A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma

Inclusion Criteria:

   - Signed Informed Consent Form

   - Age ≥ 18 years

   - Documented ovarian, primary peritoneal, or fallopian tube carcinoma that has recurred

   - No prior chemotherapy in the recurrent setting

   - Measurable disease

   - Recovered from prior radiation therapy or surgery

Exclusion Criteria:

   - Prior chemotherapy treatment for recurrent ovarian, primary peritoneal, or fallopian
   tube carcinoma

   - History of abdominal fistula, gastrointestinal perforation (GIP), or intra-abdominal
   abscess

   - Patients with clinical symptoms or signs of gastrointestinal (GI) obstruction or who
   require parenteral hydration, parenteral nutrition, or tube feeding

   - Patients with evidence of abdominal free air not explained by paracentesis or recent
   surgical procedure

   - Current, recent, or planned participation in an experimental drug study

   - History of systemic bevacizumab (Avastin) or other vascular endothelial growth factor
   (VEGF) or VEGF receptor-targeted agent use

   - Inadequately controlled hypertension

   - Prior history of hypertensive crisis or hypertensive encephalopathy

   - New York Heart Association Class II or greater congestive heart failure (CHF)

   - History of myocardial infarction or unstable angina

   - History of stroke or transient ischemic attack (TIA)

   - Known central nervous system (CNS) disease except for treated brain metastasis

   - Significant vascular disease or recent peripheral arterial thrombosis

   - History of hemoptysis

   - Evidence of bleeding diathesis or significant coagulopathy (in the absence of
   therapeutic anticoagulation)